Cure My Disease

Don't miss your cure!

 Log in / Sign up

Off-the-Shelf CAR-Ts take on lupus and more

NCT ID NCT07596680

Not yet recruiting Disease control Sponsor: Nanjing Bioheng Biotech Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 2 times

Summary

This early-phase trial tests a single dose of universal (off-the-shelf) CAR-T cells in 30 adults with active autoimmune diseases like lupus, scleroderma, vasculitis, myositis, or Sjögren's. The treatment targets CD19 and BCMA on immune cells to reset the faulty immune system. The goal is to reduce disease activity and possibly achieve drug-free remission, but lifelong management may still be needed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANCA-ASSOCIATED VASCULITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired idiopathic inflammatory myopathy anti-neutrophil cytoplasmic antibody-associated vasculitis granulomatosis with polyangiitis myositis disease Sjogren syndrome systemic lupus erythematosus systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANCA-ASSOCIATED VASCULITIS IDIOPATHIC INFLAMMATORY MYOPATHIES SJÖGREN SYNDROME SLE - SYSTEMIC LUPUS ERYTHEMATOSUS SYSTEMIC SCLEROSIS

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, 220127, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.